Reimbursement is a major barrier to primary care practitioner treatment of hepatitis C virus (HCV) infection, along with purported barriers such as complexity of the patients, time commitment, and the need for expertise. This according a recent nationwide survey of general practitioners that sought to identify barriers to HCV treatment among general practitioners. Among the details:
- 3,817 general practitioners were surveyed; 925 (24.2%) participated.
- 187 (21%) practitioners indicated they prescribed HCV medications.
- 620 (70%) indicated that no general practitioner in their practice had interest in managing HCV therapy.
- HCV training was associated with increased prescribing activity.
- Inadequate reimbursement (44%), too few HCV patients (40%), and caseload with other patients (40%) were the most frequently identified barriers to treatment.
- A lack of awareness to the prevalence of HCV in the general population was also identified as an important barrier.
Johnson S, Aluzaite K, Taar A, Schultz M. Identifying barriers to treatment of HCV in the primary care setting. [Published online ahead of print October 30, 2018]. Hepatol Int. doi:10.1007/s12072-018-9902-x.
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al